Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB598 · 1 trial · 12 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Cohort 1 | EXPERIMENTAL | Participants will receive AB598 intravenous (IV) infusion once every 3 weeks |
| Dose Escalation Cohort 2 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Dose Escalation Cohort 3 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Dose Escalation Cohort 4 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Pharmacodynamic Cohort 1 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Pharmacodynamic Cohort 2 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Pharmacodynamic Cohort 3 | EXPERIMENTAL | Participants will receive AB598 IV infusion once every 3 weeks |
| Dose Expansion Gastric/GEJ Cancer (phase 1b) | EXPERIMENTAL | Participants will receive AB598 IV infusion every 2 weeks in combination with zimberelimab and FOLFOX (oxaliplatin, leucovorin, fluorouracil) |
| Name | Type | Description |
|---|---|---|
| AB598 | DRUG | Administered as specified in the treatment arm |
| Zimberelimab | DRUG | Administered as specified in the treatment arm |
| Fluorouracil | DRUG | Administered as specified in the treatment arm |
| Leucovorin | DRUG | Administered as specified in the treatment arm |
| Oxaliplatin | DRUG | Administered as specified in the treatment arm |
Key Inclusion Criteria: * Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) guidance * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Prior systemic radiation or whole brain radiation therapy must have been completed at ...
Top 2 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AB598 is an investigational small molecule being studied for the treatment of advanced cancers, including bladder, cervical, esophageal, gastric, gastroesophageal-junction, head and neck squamous cell carcinoma, non-small cell lung, ovarian, renal cell, and triple negative breast cancers. It is currently in Phase 1 clinical development and is not yet approved.
AB598 targets CD39, a cell surface enzyme involved in the adenosine pathway that can suppress anti-tumor immune responses. By inhibiting CD39, AB598 is designed to modulate the tumor microenvironment and potentially enhance the body's immune response against cancer cells.
AB598 is being developed by Arcus Biosciences, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol RCUS. The company is conducting clinical trials to evaluate the safety and efficacy of AB598 in patients with advanced malignancies.
AB598 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being evaluated in clinical trials for safety and preliminary efficacy in patients with advanced cancers.
AB598 is being studied in a Phase 1 clinical trial with the identifier NCT05891171, titled 'Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers.' The trial is active but not recruiting, with an estimated enrollment of 40 participants across the United States, Australia, and Taiwan.
AB598 is a distinct investigational small molecule targeting CD39. No alternative names for AB598 have been disclosed in the available clinical trial information. It is being evaluated as a monotherapy and in combination with other agents in the ongoing Phase 1 study.